Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)BOM:524470 +0.08%86 Return-on-Tangible-Equity is 24.29% as of Mar. 2026, which is 151% above its 10-year median of 9.68. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹20.19 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 901 Drug Manufacturers companies, Syncom Formulation (India) ranks better than 78.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Syncom Formulation (India)'s annualized net income for the quarter that ended in Mar. 2026 was ₹1,007 Mil. Syncom Formulation (India)'s average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹4,146 Mil. Therefore, Syncom Formulation (India)'s annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 24.29%.
The historical rank and industry rank for Syncom Formulation (India)'s Return-on-Tangible-Equity or its related term are showing as below:
BOM:524470'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.33 Med: 9.68 Max: 20.2
Current: 20.2
During the past 13 years, Syncom Formulation (India)'s highest Return-on-Tangible-Equity was 20.20%. The lowest was 7.33%. And the median was 9.68%.
BOM:524470's Return-on-Tangible-Equity is ranked better than 78.91% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.87
vs BOM:524470: 20.20
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Syncom Formulation (India) Return-on-Tangible-Equity Related Terms
Syncom Formulation (India) Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524470 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 24.29% mean?
Syncom Formulation (India) (BOM:524470) has a Return-on-Tangible-Equity of 24.29% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syncom Formulation (India) and its competitors. This is 151% above median its historical median of 9.68. Over the past decade, Syncom Formulation (India)'s Return-on-Tangible-Equity has ranged from 7.33 to 20.20. According to the industry distribution chart, Syncom Formulation (India) ranks #190 out of 901 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Syncom Formulation (India)'s Return-on-Tangible-Equity too high?
Syncom Formulation (India)'s current Return-on-Tangible-Equity of 24.29% is 151% above median its 10-year median of 9.68. Over the past 10 years, this metric has ranged from a low of 7.33 to a high of 20.20. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.87. Syncom Formulation (India)'s value of 24.29% is 208.6% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #190 out of 901 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #190 out of 901 companies for Return-on-Tangible-Equity. This places Syncom Formulation (India) in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.87. Syncom Formulation (India)'s value of 24.29% is 208.6% above this benchmark. Historically, Syncom Formulation (India)'s own Return-on-Tangible-Equity has ranged from 7.33 to 20.20 over the past decade. While the company's 10-year median is 9.68 vs. the industry median of 7.87, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.87, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current Return-on-Tangible-Equity of 24.29% is 208.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current Return-on-Tangible-Equity is 24.29%, which is 151% above median its own 10-year median of 9.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹20.19, compared to a current price of ₹13.16 — trading 34.8% below its estimated fair value. The current Return-on-Tangible-Equity is 24.29%, which is 151% above median its 10-year median of 9.68 and 208.6% above the Drug Manufacturers industry median of 7.87. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Return-on-Tangible-Equity is 24.29% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹13.16 is trading 34.8% below its estimated GF Value™ of ₹20.19.
GuruFocus considers Syncom Formulation (India) to be Significantly Undervalued.
Key valuation signals for BOM:524470:
Return-on-Tangible-Equity: 24.29% (151% above median its 10-year median of 9.68)
GF Value™: ₹20.19 vs. price of ₹13.16 (34.8% below fair value)
Industry Position: 208.6% above the Drug Manufacturers median (#190 of 901)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score
Get the complete analysis for BOM:524470
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
